Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Reducing low-density lipoprotein cholesterol (LDL-C) levels is crucial to the prevention of atherosclerotic cardiovascular disease (ASCVD). However, many patients, especially those at very high ASCVD risk or with familial hypercholesterolemia (FH), do not achieve target LDL-C levels with statin mono...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/15/5082 |
| _version_ | 1797586500824596480 |
|---|---|
| author | Farzahna Mohamed Brett Mansfield Frederick J. Raal |
| author_facet | Farzahna Mohamed Brett Mansfield Frederick J. Raal |
| author_sort | Farzahna Mohamed |
| collection | DOAJ |
| description | Reducing low-density lipoprotein cholesterol (LDL-C) levels is crucial to the prevention of atherosclerotic cardiovascular disease (ASCVD). However, many patients, especially those at very high ASCVD risk or with familial hypercholesterolemia (FH), do not achieve target LDL-C levels with statin monotherapy. The underutilization of novel lipid-lowering therapies (LLT) globally may be due to cost concerns or therapeutic inertia. Emerging approaches have the potential to lower LDL-C and reduce ASCVD risk further, in addition to offering alternatives for statin-intolerant patients. Shifting the treatment paradigm towards initial combination therapy and utilizing novel LLT strategies can complement existing treatments. This review discusses innovative approaches including combination therapies involving statins and agents like ezetimibe, bempedoic acid, cholesterol ester transfer protein (CETP) inhibitors as well as strategies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) and angiopoietin-like protein 3 (ANGPTL3) inhibition. Advances in nucleic acid-based therapies and gene editing are innovative approaches that will improve patient compliance and adherence. These strategies demonstrate significant LDL-C reductions and improved cardiovascular outcomes, offering potential for optimal LDL-C control and reduced ASCVD risk. By addressing the limitations of statin monotherapy, these approaches provide new management options for elevated LDL-C levels. |
| first_indexed | 2024-03-11T00:23:09Z |
| format | Article |
| id | doaj.art-21aba9b7cfd84786a68c7fae4fa10a16 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T00:23:09Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-21aba9b7cfd84786a68c7fae4fa10a162023-11-18T23:09:09ZengMDPI AGJournal of Clinical Medicine2077-03832023-08-011215508210.3390/jcm12155082Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein CholesterolFarzahna Mohamed0Brett Mansfield1Frederick J. Raal2Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South AfricaDivision of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South AfricaDivision of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South AfricaReducing low-density lipoprotein cholesterol (LDL-C) levels is crucial to the prevention of atherosclerotic cardiovascular disease (ASCVD). However, many patients, especially those at very high ASCVD risk or with familial hypercholesterolemia (FH), do not achieve target LDL-C levels with statin monotherapy. The underutilization of novel lipid-lowering therapies (LLT) globally may be due to cost concerns or therapeutic inertia. Emerging approaches have the potential to lower LDL-C and reduce ASCVD risk further, in addition to offering alternatives for statin-intolerant patients. Shifting the treatment paradigm towards initial combination therapy and utilizing novel LLT strategies can complement existing treatments. This review discusses innovative approaches including combination therapies involving statins and agents like ezetimibe, bempedoic acid, cholesterol ester transfer protein (CETP) inhibitors as well as strategies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) and angiopoietin-like protein 3 (ANGPTL3) inhibition. Advances in nucleic acid-based therapies and gene editing are innovative approaches that will improve patient compliance and adherence. These strategies demonstrate significant LDL-C reductions and improved cardiovascular outcomes, offering potential for optimal LDL-C control and reduced ASCVD risk. By addressing the limitations of statin monotherapy, these approaches provide new management options for elevated LDL-C levels.https://www.mdpi.com/2077-0383/12/15/5082dyslipidemiabempedoic acidPCSK9 inhibitorsANGPTL3 inhibitors |
| spellingShingle | Farzahna Mohamed Brett Mansfield Frederick J. Raal Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol Journal of Clinical Medicine dyslipidemia bempedoic acid PCSK9 inhibitors ANGPTL3 inhibitors |
| title | Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol |
| title_full | Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol |
| title_fullStr | Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol |
| title_full_unstemmed | Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol |
| title_short | Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol |
| title_sort | targeting pcsk9 and beyond for the management of low density lipoprotein cholesterol |
| topic | dyslipidemia bempedoic acid PCSK9 inhibitors ANGPTL3 inhibitors |
| url | https://www.mdpi.com/2077-0383/12/15/5082 |
| work_keys_str_mv | AT farzahnamohamed targetingpcsk9andbeyondforthemanagementoflowdensitylipoproteincholesterol AT brettmansfield targetingpcsk9andbeyondforthemanagementoflowdensitylipoproteincholesterol AT frederickjraal targetingpcsk9andbeyondforthemanagementoflowdensitylipoproteincholesterol |